HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO CARsgen Therapeutics - Insights on Pipeline and Challenges

Bloomage Biotechnology (688363.CH) - Opportunities Coexist with Challenges

Shanghai Junshi Bioscience - Here Are the Challenges

Pre-IPO BeiGene - Would the IPO on the STAR Market Be the Last Hurrah?

Innovent Biologics (1801 HK) - Have the Genes to Become a Big Pharma

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Equity Bottom-Up

Jiangsu Hengrui Medicine / Equity Bottom-Up

<p>Recently, <a href="https://www.smartkarma.com/entities/jiangsu-hengrui-medicine-co-ltd" target="_blank" data-smartkarma-citation="entities:14128:1" rel="noopener">Jiangsu Hengrui Medicine (600276 CH)</a>'s share price has seen a significant pullback. Since April 9<sup>th</sup>, 2021, the Company's stock price had fallen for six consecutive trading days, with a cumulative decline of more than 10%, and its market value dropped by about RMB63 billion. So what happened to Hengrui? And what is the future business prospects of this Company? The following mainly included some important insights that deserve to pay attention to.</p>

Recently, Jiangsu Hengrui Medicine (600276 CH)'s share price has seen a significant pullback. Since April 9th, 2021, the Company's stock price had fallen for six consecutive trading days, with a cumulative decline of more than 10%, and its market value dropped by about RMB63 billion. So what happened to Hengrui? And what is the future business prospects of this Company? The following mainly included some important insights that deserve to pay attention to.

Jiangsu Hengrui Medicine (600276.CH) - Insights on Recent Pullback and Future Business Prospects